R&D channel feed – Endpoints News

R&D channel feed

Biogen signals a big PhIII failure as the lead gene therapy in their $800M Nightstar buyout goes down in flames

5 years ago

Terns Pharmaceuticals touts safety data from an ex-Eli Lilly candidate in the hunt for NASH treatment

5 years ago

In next-gen BTK battle, AbbVie and J&J tout pivotal data backing Imbruvica as a combo treatment

5 years ago

Months after FDA rejection, Sanofi touts pivotal win for rare disease drug sutimlimab as it preps to refile

5 years ago

Vertex and CRISPR Therapeutics unveil more positive gene therapy data, but busulfan again casts a shadow over the field

5 years ago

Vertex strikes out on its latest big shot at a rare genetic disease. But they're going to keep on swinging

5 years ago

An API firm with a history of J&J funding scores a major loan to advance its portfolio

5 years ago

With its controversial aducanumab approval in hand, Biogen gears up for a quick US rollout

5 years ago

Bristol Myers' CAR-T Breyanzi busts out a win in earlier-line lymphoma, potentially cracking open an expanded market

5 years ago

AGC adds another major Covid-19 vaccine maker to the client list with BioNTech pact for plasmid DNA

5 years ago

FDA dips its toe into the world of patient-reported outcomes for cancer trials

5 years ago

With its eyes set on an IPO raise, InCarda unrolls mid-stage data backing inhaled arrhythmia drug

5 years ago

US to shell out $1.2B for supplies of Merck's potential Covid-19 antiviral

5 years ago

Trailing the Big Pharma players, a lesser known BCMA CAR-T candidate comes into the spotlight

5 years ago

Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test

5 years ago

#ASCO21: AstraZeneca takes a swing at J&J and AbbVie's Imbruvica with long-term data from head-to-head trial

5 years ago

FDA OKs aducanumab for Alzheimer's, turning controversial Biogen drug into a megablockbuster

5 years ago

FDA lets bluebird resume trials for sickle cell gene therapy after cancer scare, but big questions linger over field

5 years ago

As head-to-head with Alexion heats up, Novartis flashes data for next wave of trials for star kidney molecule

5 years ago

#ASCO21: A week after nabbing priority review, Kite unveils the pivotal data it hopes will lead to a new CAR-T approval

5 years ago

#ASCO21: Eli Lilly-partnered Merus reveals new data for NRG1 fusion cancers including pancreatic and NSCLC

5 years ago

Whatever the FDA decides on aducanumab, Alzheimer's research is finally, mostly, kind of moving beyond the amyloid hypothesis

5 years ago

#ASCO21: AstraZeneca's PD-L1 Imfinzi tacks on 5-year survival data in NSCLC, which it's calling 'unprecedented'

5 years ago

#ASCO21: Gilead's Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients

5 years ago

First page Previous page 167 168 169170171 172 173 Next page Last page